DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17. https://doi.org/10.1182/blood-2018-08-868752

Article  CAS  PubMed  PubMed Central  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629

Article  CAS  PubMed  Google Scholar 

Dandona R, Rewari BB, Kumar GA, Tanwar S, Kumar SGP, Vishnumolakala VS et al (2016) Survival outcomes for first-line antiretroviral therapy in India’s ART program. BMC Infect Dis 16(1):555. https://doi.org/10.1186/s12879-016-1887-2

Article  PubMed  PubMed Central  Google Scholar 

Sutton L, Guénel P, Tanguy ML, Rio B, Dhedin N, Casassus P et al (2001) Acute myeloid leukaemia in human immunodeficiency virus-infected adults: epidemiology, treatment feasibility and outcome. Br J Haematol 112(4):900–908

Article  CAS  PubMed  Google Scholar 

Aboulafia DM, Meneses M, Ginsberg S, Siegel MS, Howard WW, Dezube BJ (2002) Acute myeloid leukemia in patients infected with HIV-1. AIDS 16(6):865–876

Article  PubMed  Google Scholar 

Ca P, Sekar WCN, Anisha N, Alecia M, Greg AL et al (2022) The BCL-2 inhibitor venetoclax augments immune effector function mediated by fas ligand, TRAIL, and perforin/granzyme B, resulting in reduced plasma viremia and decreased HIV reservoir size during acute hiv infection in a humanized mouse model. J Virol 96(24):e01730-22. https://doi.org/10.1128/jvi.01730-22

Article  CAS  Google Scholar 

Alto A, Natesampillai S, Chandrasekar AP, Krogman A, Misra A, Shweta F et al (2021) The combination of venetoclax and ixazomib selectively and efficiently kills HIV-infected cell lines but has unacceptable toxicity in primary cell models. J Virol 95(12):10–1128

Article  Google Scholar 

Arandjelovic P, Kim Y, Cooney JP, Preston SP, Doerflinger M, McMahon JH et al (2023) Venetoclax, alone and in combination with the BH3 mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice. Cell Rep Med 4(9):101178

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans MW, Sung A, Gojo I, Tidwell ML, Greer J, Levis M et al (2009) Human immunodeficiency virus (HIV)-associated acute myeloid leukemia (AML) in the era of highly active antiretroviral therapy (HAART): high complete remission rate, but poor tolerance of consolidation therapy and short disease-free survival. Blood 114(22):4126. https://doi.org/10.1182/blood.V114.22.4126.4126

Article  Google Scholar 

Forghieri F, Nasillo V, Bettelli F, Pioli V, Giusti D, Gilioli A et al (2020) Acute myeloid leukemia in patients living with HIV Infection: several questions, fewer answers. Int J Mol Sci. 21:3

Article  Google Scholar 

Kalaiyarasi JP, Ganesan P, Kannan K, Ganesan TS, Radhakrishnan V, Dhanushkodi M et al (2019) Outcomes of intensive treatment of adult acute myeloid leukemia patients: a retrospective study from a single centre. Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus 35(2):248–254

Article  Google Scholar 

Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA et al (2015) Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 170(1):110–117

Article  PubMed  PubMed Central  Google Scholar 

Murali NA, Ganesan P, Vijayakumar V, Kannan K, Radhakrishnan V, Ganesan TS et al (2016) Increasing incidence of multidrug-resistant gram-negative septicaemia during induction therapy of acute myeloid leukaemia. J Hosp Infect 93:314–315

Article  CAS  PubMed  Google Scholar 

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454–464. https://doi.org/10.1056/NEJMoa1614359

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jonas BA, Pollyea DA (2019) How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33(12):2795–2804. https://doi.org/10.1038/s41375-019-0612-8

Article  CAS  PubMed  Google Scholar 

Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM et al (2021) Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25. https://doi.org/10.1038/s41408-021-00410-w

Article  PubMed  PubMed Central  Google Scholar 

Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T et al (2022) Hypomethylating agent and venetoclax with FLT3 inhibitor triplet therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77

Article  PubMed  PubMed Central  Google Scholar